Provigil Likely To Add Two New Claims; Broad Sleepiness Indication May Wait
Executive Summary
Cephalon expects that Provigil (modafinil) will receive an "approvable" letter on Oct. 20 for use in sleep disruption and circadian misalignment, CEO Frank Baldino said during a Sept. 25 conference call following an advisory committee review of expanded labeling for the narcolepsy agent
You may also be interested in...
Cephalon Launches Provigil Label Expansion; DTC Campaign Possible
Cephalon is launching its expanded Provigil label with a focus on educating physicians on sleepiness
Cephalon Launches Provigil Label Expansion; DTC Campaign Possible
Cephalon is launching its expanded Provigil label with a focus on educating physicians on sleepiness
Cephalon Preps For Provigil Label Expansion, Wins Bid For CIMA
Cephalon is enlarging its sales force to 500 reps in anticipation of FDA approval for an expanded wakefulness indication for Provigil, CEO Frank Baldino told analysts Nov. 3